Gsk Plc-spon Adr. share price today

(GSK)

Gsk Plc-spon Adr. share price is $34.17 & ₹2,896.28 as on 13 Dec 2024, 2.30 'hrs' IST

$34.17

▲

-0.28

(-0.81%)

Market is closed - opens 8 PM, 13 Dec 2024

View live Gsk Plc-spon Adr. share price in Dollar and Rupees. Guide to invest in Gsk Plc-spon Adr. from India. Also see the sentimental analysis on Indian investors investing in Gsk Plc-spon Adr.. Get details on the Indian mutual funds that are investing in Gsk Plc-spon Adr.. Get Analyst recommendations and forecasts along with all the Gsk Plc-spon Adr.'s financials.

Gsk Plc-spon Adr. share price movements

$34.09
$34.43
$34.17
0.25%
Downside
Day's Volatility :1.0%
Upside
0.76%
$32.83
$45.93
$34.17
3.94%
Downside
52 Weeks Volatility :28.52%
Upside
25.6%

Gsk Plc-spon Adr. Returns

Period	Gsk Plc-spon Adr.	Russel 2000	Index (Russel 2000)
3 Months	-20.55%	0.0%	0.0%
6 Months	-15.94%	0.0%	0.0%
1 Year	-7.6%	0.0%	0.0%
3 Years	-36.28%	-18.9%	-18.9%

Gsk Plc-spon Adr. Key Statistics

in dollars & INR

Previous Close	$34.45
Open	$34.27
Today's High	$34.43
Today's Low	$34.085
Market Capitalization	$71.4B
Today's Volume	$3.4M
52 Week High	$45.925
52 Week Low	$32.825
Revenue TTM	$31.3B
EBITDA	$9.3B
Earnings Per Share (EPS)	$1.55
PE Ratio	22.23
Dividend Yield	4.54%
Profit Margin	8.02%
Quarterly Earnings Growth YOY	-0.28%
Return On Equity TTM	21.85%

How to invest in Gsk Plc-spon Adr. from India?

It is very easy for Indian residents to invest directly in Gsk Plc-spon Adr. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Gsk Plc-spon Adr. stock in both rupees (INR) and dollars (USD). Search for Gsk Plc-spon Adr. or GSK on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Gsk Plc-spon Adr. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Gsk Plc-spon Adr. shares which would translate to 0.025 fractional shares of Gsk Plc-spon Adr. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Gsk Plc-spon Adr.

20.29%

Period: Sep 13, 2024 to Dec 12, 2024. Change in 30 Days versus previous period

Investment in Gsk Plc-spon Adr. from India has grown in the last 30 days as on Dec 13, 2024. 20.29% more purchase transactions for Gsk Plc-spon Adr. in the last 30 days versus the previous period.

68%

Period: Sep 13, 2024 to Dec 12, 2024. Change in 30 Days versus previous period

Search volume for Gsk Plc-spon Adr. on INDmoney from India has grown in the last 30 days as on Dec 13, 2024. 68% more investors are searching Gsk Plc-spon Adr. in the last 30 days versus the previous period.

Global Institutional Holdings in Gsk Plc-spon Adr.

Dodge & Cox
3.34%
FMR Inc
1.42%
JTC Employer Solutions Trustee Ltd
1.00%
Fisher Asset Management, LLC
0.91%
PRIMECAP Management Company
0.73%
Morgan Stanley - Brokerage Accounts
0.39%

Analyst Recommendation on Gsk Plc-spon Adr.

Buy

60%Buy

30%Hold

9%Sell

Based on 33 Wall street analysts offering stock ratings for Gsk Plc-spon Adr.(by analysts ranked 0 to 5 stars)

Based on 33 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Gsk Plc-spon Adr.

What analysts predicted

Upside of 31.91%

Current:

$34.17

Target:

$45.07

Insights on Gsk Plc-spon Adr.

Price Movement
In the last 3 months, GSK stock has moved down by -20.6%
Increasing Revenue
GSK Plc's revenue has shown consistent growth over the last four quarters. It increased from $7.36 billion to $8.01 billion, which represents an average increase of 2.7% each quarter.
Decreasing Net Profit
GSK Plc's net profit has been declining over the last three quarters. It started at $1.17 billion and fell to $58 million, averaging a decrease of 52.5% each quarter.
GSK vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 30.9% return, outperforming this stock by 37.9%
GSK vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 214.8% return, outperforming this stock by 251.4%
Price to Sales
GSK Plc's sponsored ADR has a Price-to-Sales Ratio of 2.2, meaning investors are willing to pay $2.2 for every $1 of sales generated by the company. In comparison, investors are paying much more for Eli Lilly And Company, at $17.2 for every $1 of sales. This indicates that GSK is currently valued much lower compared to Eli Lilly based on their sales performance.

Gsk Plc-spon Adr. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$39.0B	↑ 2.1%
Net Income	$4.6B	↑ 136.49%
Net Profit Margin	11.75%	↑ 6.67%

	FY19	Y/Y Change
Revenue	$44.2B	↑ 9.52%
Net Income	$6.1B	↑ 28.21%
Net Profit Margin	13.76%	↑ 2.01%

	FY20	Y/Y Change
Revenue	$45.8B	↑ 1.02%
Net Income	$7.7B	↑ 23.77%
Net Profit Margin	16.86%	↑ 3.1%

	FY21	Y/Y Change
Revenue	$45.4B	↑ 0.04%
Net Income	$5.8B	↓ 23.73%
Net Profit Margin	12.85%	↓ 4.01%

	FY22	Y/Y Change
Revenue	$35.7B	↓ 14.04%
Net Income	$18.2B	↑ 241.07%
Net Profit Margin	51.0%	↑ 38.15%

	FY23	Y/Y Change
Revenue	$38.4B	↑ 3.42%
Net Income	$6.2B	↓ 67.05%
Net Profit Margin	16.25%	↓ 34.75%

	Q2 FY23	Q/Q Change
Revenue	$10.3B	↑ 17.21%
Net Income	$1.8B	↓ 1.74%
Net Profit Margin	17.97%	↓ 3.47%

	Q3 FY23	Q/Q Change
Revenue	$10.0B	↓ 1.17%
Net Income	$434.4M	↓ 76.09%
Net Profit Margin	4.35%	↓ 13.62%

	Q4 FY23	Q/Q Change
Revenue	$9.3B	↓ 8.56%
Net Income	$1.3B	↑ 198.86%
Net Profit Margin	14.21%	↑ 9.86%

	Q1 FY24	Q/Q Change
Revenue	$10.0B	↑ 7.08%
Net Income	$1.5B	↑ 12.14%
Net Profit Margin	14.88%	↑ 0.67%

	Q2 FY24	Q/Q Change
Revenue	$10.2B	↑ 1.62%
Net Income	$-73.7M	↓ 104.94%
Net Profit Margin	-0.72%	↓ 15.6%

	Q3 FY24	Q/Q Change
Revenue	$8.0B	↑ 0.0%
Net Income	$-58.0M	↑ 0.0%
Net Profit Margin	-0.72%	↑ 0.0%

	FY18	Y/Y Change
Profit	$26.1B	↑ 3.71%

	FY19	Y/Y Change
Profit	$28.7B	↑ 6.37%

	FY20	Y/Y Change
Profit	$30.1B	↑ 2.3%

	FY21	Y/Y Change
Profit	$29.9B	↑ 0.52%

	FY22	Y/Y Change
Profit	$24.1B	↓ 12.18%

	FY23	Y/Y Change
Profit	$27.6B	↑ 10.08%

	Q2 FY23	Q/Q Change
Profit	$7.4B	↑ 17.31%

	Q3 FY23	Q/Q Change
Profit	$7.1B	↓ 2.74%

	Q4 FY23	Q/Q Change
Profit	$6.9B	↓ 5.04%

	Q1 FY24	Q/Q Change
Profit	$7.4B	↑ 6.95%

	Q2 FY24	Q/Q Change
Profit	$7.1B	↓ 3.24%

	Q3 FY24	Q/Q Change
Profit	$5.6B	↑ 0.0%

	FY18	Y/Y Change
Operating Cash Flow	$10.7B	↑ 21.73%
Investing Cash Flow	$-2.0B	↑ 7.62%
Financing Cash Flow	$-8.1B	↑ 0.14%

	FY19	Y/Y Change
Operating Cash Flow	$10.5B	↓ 4.76%
Investing Cash Flow	$-7.0B	↑ 244.75%
Financing Cash Flow	$-2.4B	↓ 71.2%

	FY20	Y/Y Change
Operating Cash Flow	$11.3B	↑ 5.25%
Investing Cash Flow	$2.9B	↓ 140.36%
Financing Cash Flow	$-13.6B	↑ 450.65%

	FY21	Y/Y Change
Operating Cash Flow	$10.6B	↓ 5.79%
Investing Cash Flow	$-2.4B	↓ 182.23%
Financing Cash Flow	$-10.1B	↓ 25.1%

	FY22	Y/Y Change
Operating Cash Flow	$9.0B	↓ 6.9%
Investing Cash Flow	$-10.7B	↑ 393.64%
Financing Cash Flow	$1.0B	↓ 110.84%

	FY23	Y/Y Change
Operating Cash Flow	$8.6B	↓ 8.58%
Investing Cash Flow	$-2.0B	↓ 81.82%
Financing Cash Flow	$-7.1B	↓ 785.42%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.7B	↑ 2366.04%
Investing Cash Flow	$-1.2B	↑ 136.27%
Financing Cash Flow	$39.1M	↓ 109.75%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$2.7B	↑ 69.24%
Investing Cash Flow	$-609.4M	↓ 49.07%
Financing Cash Flow	$-2.2B	↓ 5783.87%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$1.2B	↓ 57.55%
Investing Cash Flow	$339.3M	↓ 154.58%
Financing Cash Flow	$-1.3B	↓ 43.87%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$1.1B	↓ 6.07%
Investing Cash Flow	$-189.4M	↓ 155.6%
Financing Cash Flow	$-1.7B	↑ 32.86%

Gsk Plc-spon Adr. Technicals Summary

Sell

Neutral

Buy

Gsk Plc-spon Adr. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Gsk Plc-spon Adr. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Gsk Plc-spon Adr.	-2.68%	-15.94%	-7.6%	-36.28%	-41.69%
Eli Lilly And Company	-3.63%	-10.94%	36.38%	213.72%	536.83%
Johnson & Johnson	-4.57%	0.48%	-6.78%	-14.12%	3.14%
Merck & Co. Inc.	2.79%	-21.8%	-4.37%	37.34%	13.39%
Novo Nordisk A/s	1.59%	-23.78%	10.83%	92.54%	273.68%
Abbvie Inc	1.67%	2.73%	11.82%	36.06%	93.66%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Gsk Plc-spon Adr.	22.23	22.23	0.76	3.9	0.22	0.07	0.05	3.43
Eli Lilly And Company	85.5	85.5	0.75	13.15	0.65	0.14	0.01	15.83
Johnson & Johnson	24.2	24.2	0.87	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.87	20.87	0.07	7.74	0.28	0.11	0.03	17.58
Novo Nordisk A/s	34.03	34.03	1.66	22.7	0.89	0.21	0.01	27.07
Abbvie Inc	60.55	60.55	0.42	10.94	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Gsk Plc-spon Adr.	Buy	$71.4B	-41.69%	22.23	8.02%
Eli Lilly And Company	Buy	$715.9B	536.83%	85.5	20.48%
Johnson & Johnson	Buy	$353.1B	3.14%	24.2	16.74%
Merck & Co. Inc.	Buy	$252.3B	13.39%	20.87	19.23%
Novo Nordisk A/s	Buy	$472.8B	273.68%	34.03	35.01%
Abbvie Inc	Buy	$308.1B	93.66%	60.55	9.22%

Gsk Plc-spon Adr. Dividend announcements

Gsk Plc-spon Adr. Dividends December, 2024
In the quarter ending December,2024. Gsk Plc-spon Adr. has declared dividend of $0.39
Read More

About Gsk Plc-spon Adr.

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.

Organization	Gsk Plc-spon Adr.
Employees	70212
CEO	Ms. Emma Natasha Walmsley
Industry	Health Technology

Management People of Gsk Plc-spon Adr.

Name	Title
Ms. Emma Natasha Walmsley	CEO & Director
Ms. Julie Belita Brown A.C.A.	CFO & Executive Director
Ms. Shobie Ramakrishnan	Chief Digital & Technology Officer
Mr. Tony Wood	Chief Scientific Officer and Head of R&D
Ms. Sarah Elton-Farr	Head of Investor Relations
Mr. James Ford	Senior VP & Group General Counsel of Legal & Compliance
Ms. Sally Jackson	Senior Vice President of Global Communications & CEO Office
Mr. David Simon Redfern BSc (Hons), CA	President of Corporate Development
Ms. Diana Conrad	Chief People Officer
Mr. Philip C. Thomson	President of Global Affairs

Important FAQs about investing in Gsk Plc-spon Adr. from India :

What is Gsk Plc-spon Adr. share price today?

Gsk Plc-spon Adr. share price today stands at $34.17, Open: $34.27 ; Previous Close: $34.45 ; High: $34.43 ; Low: $34.09 ; 52 Week High: $45.93 ; 52 Week Low: $32.83. The stock opens at $34.27, after a previous close of $34.45. The stock reached a daily high of $34.43 and a low of $34.09, with a 52-week high of $45.93 and a 52-week low of $32.83.

Can Indians buy Gsk Plc-spon Adr. shares?

Yes, Indians can invest in the Gsk Plc-spon Adr. (GSK) from India.

With INDmoney, you can buy Gsk Plc-spon Adr. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Gsk Plc-spon Adr. at zero transaction cost.

How can I buy Gsk Plc-spon Adr. shares from India?

It is very easy to buy Gsk Plc-spon Adr. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Gsk Plc-spon Adr. be purchased?

Yes, you can buy fractional shares of Gsk Plc-spon Adr. with INDmoney app.

What are the documents required to start investing in Gsk Plc-spon Adr. stocks?

To start investing in Gsk Plc-spon Adr., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.